Healthcare

FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 24, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications today announced that […]